Authors
Elisa Monti, Marco Bella, Clara Vianello, Giuseppe Galvani, Alice Brighenti, Carla Serra, Andrea Boccatonda, Francesca Fornari
Published in
Biomarker research. Volume 14. Issue 1. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, largely due to tumor heterogeneity, late diagnosis, and high recurrence rates even after curative treatment. Although HCC is potentially curable when detected at an early stage, suboptimal surveillance, particularly in patients with underlying cirrhosis or metabolic risk factors, limits the proportion of patients eligible for curative therapies. Current surveillance strategies for at-risk populations have intrinsic limitations, and the performance of imaging and serum biomarkers remains suboptimal. Moreover, the lack of reliable prognostic biomarkers for detecting early recurrence hampers post-treatment surveillance and impacts clinical outcomes. In this context, circulating biomarkers have emerged as promising tools for improving both early detection and prognostic stratification. Liquid biopsy has the potential to enable early, non-invasive diagnosis of HCC and allows longitudinal assessment of tumor progression through serial sampling. In early-stage HCC, blood candidates may complement or outperform conventional approaches by enabling earlier diagnosis and more accurate risk stratification. In this review, we summarize recent advances and current challenges in the clinical translation of circulating biomarkers. We focus on key liquid biopsy components, including circulating cell-free DNA, particularly circulating tumor DNA, circulating tumor cells, non-coding RNAs, extracellular vesicles, proteins and metabolites, such as bile acids and lipids, highlighting their diagnostic and prognostic potential and their possible integration into personalized management strategies for patients with early-stage HCC.
PMID:
43053253
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0